Theralase® Investor Conference Call Reminder

Nov 17, 2025 7:00 AM EST Theralase(R) Reminds Investors of Conference Call to Provide Update on Study II Interim Data Demonstrating 64.3% Complete Response Toronto, Ontario–(Newsfile Corp. – November 17, 2025) – Theralase® Technologies Inc. (“ ” or the “ “), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses reminds investors that it will host a conference call on to provide an update on the Company’s ongoing Phase II clinical study for patients diagnosed with Bacillus Calmette-Guérin (“ “)-Unresponsive Non-Muscle Invasive Bladder Cancer (“ “) Carcinoma In-Situ (“ “) (“ “), along with a review of financial and operational results for the fiscal quarter ended September 30, 2025. (TSXV: TLT) (OTCQB: TLTFF) Theralase® Company Wednesday, November 19th at 11:00 am ET BCG NMIBC CIS Study II Participants are encouraged to submit questions in advance to to ensure sufficient time for discussion. [email protected] Zoom Meeting Link: Webinar ID: 810 4484 1120 https://us02web.zoom.us/j/81044841120 Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) – not required for those attending by Zoom An archived version will be available on the website following the conference call. Study II Update: As of : November 7, 2025 have been treated with the primary Study Procedure, representing of the targeted enrollment of 90 patients 88 patients 97.8% have completed the clinical study, having been assessed at all required visits or removed by the principal investigator for lack of response 72 patients remain pending study completion 16 patients Interim Clinical Results Demonstrate: of patients achieved a at any point in time. 64.3% (54/84) Complete Response (“CR”) achieved a . 72.6% (61/84) Total Response (TR = CR + Indeterminate Response (“IR”)) At the , 450-day assessment of patients maintained a CR 40% (18/45) maintained a TR, demonstrating durability of response. 42.2% (19/45) of patients maintained a CR 40% (18/45) maintained a TR, demonstrating durability of response. 42.2% (19/45) Theralase® remains on track to , with . complete enrollment in 4Q2025 data lock and regulatory submissions expected in 1Q2027 Financial Update: Theralase® has released its unaudited, condensed, consolidated, interim for the period ended September 30, 2025. 3Q2025 financial statements Financial Highlights – Nine Months Ended September 30, 2025 versus 2024: Revenue decreased to from $622,984. 5% $590,573 Cost of sales decreased to (51% of revenue). 10% $299,743 Gross margin remained stable at (49% of revenue). $290,830 Selling expenses decreased to . 18% $212,421 Administrative expenses increased to . 12% $1,444,687 Research and development expenses increased to , reflecting increased activity to support Study II progress. 1% $2,116,540 Net loss increased to , including in non-cash expenses such as amortization and stock-based compensation. 3% $3,435,145 $708,521 Operational Highlights: raised via non-brokered private placement (July 28, 2025) $672,627 completed August 29, 2025 Warrant extensions in outstanding short-term loans as of November 7, 2025 at 15% interest $280,000 The Company continues to evaluate to support clinical and commercial milestones equity and non-dilutive funding opportunities , please refer to the Company’s (“ “) available at . For additional information Management’s Discussion and Analysis MD&A www.sedarplus.ca About Ruvidar®: Ruvidar® (TLD-1433) is a small molecule, able to be activated by light, radiation, sound and other drugs, intended for the safe and effective destruction of cancer, bacteria and viruses. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of cancer, bacteria and viruses, with minimal impact on surrounding healthy tissue. Additional information is available at and . www.theralase.com www.sedarplus.ca Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This news release contains Forward-Looking Statements (“ “) within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company’s proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words “ , “ “, “ “, “ “, “ “, “ “, “ “, “ “, “ ” and similar expressions; including, statements related to the current expectations of the Company’s management regarding future research, development and commercialization of the Company’s small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. FLS may should will anticipates believes plans expects estimate potential for These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company’s operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company’s small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company’s ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company’s ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries – Theralase Technologies . For More Information: 1.866.THE.LASE (843.5273) 416.699.LASE (5273) www.theralase.com Kristina Hachey, CPA Chief Financial Officer X 224 [email protected] To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274715

The release as fetched from its publisher. theralase.com ↗